The Log book for the secondary prevention of coronary artery disease: A pilot study

Aurélien Vaillant1, Gilles Dentan2, Yves Laurent3

  • 1Département de médecine générale, UFR sciences de santé, 7, boulevard Jeanne-d'Arc, 21000 Dijon, France.

Presse Medicale (Paris, France : 1983)
|July 7, 2015
PubMed

Insights

A pilot study found that a Log book (LB) for coronary artery disease patients after myocardial infarction (MI) improved patient engagement and health outcomes, showing promise for secondary prevention.

Area of Science:

  • Cardiology
  • Public Health
  • Health Informatics

Background:

  • Secondary prevention (SP) of coronary artery disease (CAD) after myocardial infarction (MI) benefits from enhanced patient knowledge and self-management.
  • A Log book (LB) was developed by healthcare professionals in Côte d'Or to support CAD patients.

Purpose of the Study:

  • To evaluate the feasibility and effectiveness of the Log book (LB) as a novel support tool for secondary prevention (SP) in patients post-acute myocardial infarction (MI).

Main Methods:

  • A prospective randomized study involving 183 patients hospitalized for acute MI.
  • Patients were assigned to receive a Log book (LB+) or not (LB-).
  • Follow-up assessments were conducted at 4 months and 1 year.

Main Results:

  • Patients using the LB (LB+) showed increased engagement with general practitioners and a trend towards more physical activity and improved HDL-cholesterol at 4 months.
  • At 1 year, LB+ patients had a significantly reduced body mass index.
  • There was a trend towards lower cardiovascular hospitalizations or death in the LB+ group.

Conclusions:

  • The Log book (LB) is a feasible and well-accepted tool for supporting secondary prevention in post-MI patients within a regional care network.
  • This pilot study suggests the Log book is a promising tool for improving patient outcomes in cardiovascular disease management.
Abstract

Related Concept Videos

Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
861
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
419
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
456
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
592
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.7K
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
996